VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection [1] [2] [3] [4].
In Vivo, VRC-01 (topical gel) protects humanized mice against vaginal HIV-1 infection[2]. VRC-01 protects nonhuman primates against mucosal challenge with chimeric SHIV[2].
In Vitro, VRC-01 binds HIV-1 gp120 IIIB with Kd values of 1.68 nM and 1.39 nM for transient and stable tobacco plant-produced VRC-01, respectively[2]. VRC-01 (1-24 h) from transient and stable tobacco plants neutralize HIV-1 BaL in TZM-bl cells with IC50 values of 0.339 μg/mL and 0.407 μg/mL, respectively[2]. VRC-01 (1-48 h) from transient tobacco plants neutralizes a panel of 10 HIV-1 Env pseudoviruses (clades A, B, C, G), while stable plant-produced VRC-01 shows slightly reduced potency against the same panel[2].
References:
[1]. Boesch AW, et al. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014;6(4):915-927.
[2]. Teh AY, et al. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J. 2014;12(3):300-311.
[3]. Sullivan MA, et al. Anti-idiotypic monobodies derived from a fibronectin scaffold. Biochemistry. 2013;52(10):1802-1813.
[4]. Stelter S, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J. 2020;18(2):402-414.
In Vivo, VRC-01 (topical gel) protects humanized mice against vaginal HIV-1 infection[2]. VRC-01 protects nonhuman primates against mucosal challenge with chimeric SHIV[2].
In Vitro, VRC-01 binds HIV-1 gp120 IIIB with Kd values of 1.68 nM and 1.39 nM for transient and stable tobacco plant-produced VRC-01, respectively[2]. VRC-01 (1-24 h) from transient and stable tobacco plants neutralize HIV-1 BaL in TZM-bl cells with IC50 values of 0.339 μg/mL and 0.407 μg/mL, respectively[2]. VRC-01 (1-48 h) from transient tobacco plants neutralizes a panel of 10 HIV-1 Env pseudoviruses (clades A, B, C, G), while stable plant-produced VRC-01 shows slightly reduced potency against the same panel[2].
References:
[1]. Boesch AW, et al. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014;6(4):915-927.
[2]. Teh AY, et al. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J. 2014;12(3):300-311.
[3]. Sullivan MA, et al. Anti-idiotypic monobodies derived from a fibronectin scaffold. Biochemistry. 2013;52(10):1802-1813.
[4]. Stelter S, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J. 2020;18(2):402-414.